- CHI Drug Discovery Chemistry
- April 20, 2017
- Dementia Discovery Fund acquires small molecule library and enters strategic partnership with Aptuit to kickstart dementia drug discovery programmes
- February 28, 2017
- Join Aptuit (Switzerland) AG/Exquiron at the SLAS2017 in Washington DC
- January 5, 2017
Collaboration is key…
Exquiron is dedicated to contract research in early stage drug discovery. Our services span from assay development and adaptation for hit finding and profiling purposes to compound selection, high throughput screening, selectivity testing and hit characterization, and SAR expansion. Our scientists will work with you to identify the most suitable approach to reach your program milestones as rapidly, efficiently and economically as possible.
Our team brings proven expertise to all areas of the hit identification process, including broad target class coverage, assay systems and technologies, assembly of compound screening decks, high throughput screening, data processing, mining and interpretation, quality control, project management, and reporting.
… we want to be your partner for drug discovery.
Please contact us to discuss your needs, send an inquiry, or to learn more about our services.
Check our site regularly for updates and news. Click here to sign up for our quarterly newsletter.
Please enjoy our latest newsletter!